Martin And Harris Annual Reports, Balance Sheet and Financials

Martin & Harris Laboratories Limited Consolidated Balance Sheet (Rs in Lakhs)

Martin & Harris Laboratories Limited Consolidated Profit & Loss Statement (Rs in Lakhs)

Martin & Harris Laboratories Limited Consolidated Cash Flow Statement (Rs in Lakhs)

Summary of the Cash Flow Statement for the years 2025 and 2024:

Cash Flow from Operating Activities

The company reported a strong increase in net profit before tax to ₹8,299.54 lakhs in FY 2024-25 compared to ₹5,522.24 lakhs in FY 2023-24. After adjusting for major non-operating incomes such as interest received (₹3,423.51 lakhs) and substantial profit on sale of assets (₹4,533.61 lakhs), along with depreciation of ₹485.64 lakhs and interest paid of ₹107.22 lakhs, the operating performance remained robust. The most significant contribution came from working capital changes, particularly a large decrease in other current financial assets amounting to ₹35,858.76 lakhs, which substantially boosted cash flow. Although there were increases in trade receivables (₹1,986.09 lakhs) and non-current financial assets (₹3,211.58 lakhs), overall cash generated from operations rose sharply to ₹28,900.02 lakhs compared to ₹3,287.19 lakhs in the previous year. After payment of income tax of ₹1,543.90 lakhs, the net cash from operating activities stood at ₹27,356.12 lakhs, reflecting a significant improvement over ₹1,900.96 lakhs in FY 2023-24.

Cash Flow from Investing Activities

Investing activities resulted in a substantial net cash outflow of ₹27,197.05 lakhs in FY 2024-25 as against an inflow of ₹2,065.65 lakhs in FY 2023-24. The primary reason for this outflow was heavy investment in bank deposits amounting to ₹36,008.41 lakhs. The company also incurred capital expenditure of ₹1,285.54 lakhs on purchase of PPE and WIP. However, this was partially offset by proceeds from sale of PPE of ₹5,789.16 lakhs, profit on sale of investments of ₹2,411.72 lakhs, interest received of ₹3,425.51 lakhs, rent received of ₹47.66 lakhs, and ₹222.84 lakhs cash acquired on acquisition of a subsidiary. Overall, despite healthy investment income and asset sale proceeds, the large deployment into bank deposits led to a significant investing cash outflow during the year.

Cash Flow from Financing Activities

Financing activities generated a net cash inflow of ₹311.35 lakhs in FY 2024-25 compared to ₹106.87 lakhs in FY 2023-24. The company reported net proceeds from short-term borrowings of ₹516.58 lakhs. However, this inflow was partially offset by interest paid of ₹107.22 lakhs, dividend payment of ₹71.93 lakhs, and buyback of shares amounting to ₹26.08 lakhs. Overall, financing activities contributed moderately to liquidity during the year.

Net Change in Cash and Cash Equivalents

Despite substantial investing outflows, strong operating cash generation supported an overall increase in cash and cash equivalents by ₹270.12 lakhs in FY 2024-25, compared to a decrease of ₹57.85 lakhs in the previous year. The closing cash balance increased significantly to ₹295.95 lakhs from ₹24.62 lakhs at the beginning of the year, indicating improved liquidity backed by strong operational performance.

Financial ratios of Martin & Harris Laboratories Limited 

Summary of the Financial Ratio for the years 2025 and 2024:

Current Ratio

The current ratio increased sharply to 20.58 in FY 2024-25 from 3.29 in FY 2023-24, indicating a very strong liquidity position. The company holds significantly higher current assets compared to current liabilities. While this reflects excellent short-term solvency, such an exceptionally high ratio may also suggest underutilisation of working capital or excess idle funds.

Debt Equity Ratio

The debt equity ratio marginally increased to 0.03 from 0.02, indicating that the company remains almost debt-free. The capital structure is highly conservative with minimal reliance on borrowings, reducing financial risk and interest burden.

Debt Service Coverage Ratio

The DSCR slightly declined to 3.70 from 3.95. However, the ratio remains comfortable, showing that the company generates sufficient earnings to meet its debt servicing obligations without stress.

Return on Equity

ROE improved significantly to 7.33% from 4.37%, reflecting better profitability for shareholders during FY 2024-25. This indicates improved earnings generation relative to shareholders’ funds.

Inventory Turnover Ratio

The inventory turnover ratio improved to 1.94 from 1.69, indicating relatively better inventory management and faster movement of stock compared to the previous year, though the ratio remains moderate.

Trade Receivables Turnover Ratio

The trade receivables turnover ratio declined drastically to 5.93 from 87.48. This significant drop suggests a considerable slowdown in collection efficiency or change in credit policy during the year, leading to longer receivable cycles.

Trade Payables Turnover Ratio

The trade payables turnover ratio decreased to 5.51 from 8.08, indicating that the company is taking slightly longer to pay its suppliers compared to the previous year, which may support working capital management.

Net Capital Turnover Ratio

The net capital turnover ratio fell sharply to 0.29 from 2.20, reflecting lower efficiency in utilizing working capital to generate revenue during FY 2024-25. This may be due to increased current assets relative to sales.

Net Profit Ratio

The net profit ratio improved substantially to 36.61% from 13.80%, indicating a strong rise in profitability margins. This suggests improved cost control, higher operating efficiency, or significant non-operating income during the year.

Return on Capital Employed

ROCE increased to 8.64% from 5.85%, indicating improved overall efficiency in generating profits from total capital employed in the business.

Return on Investments

Return on investments improved to 2.79% from 1.60%, reflecting better returns earned from the company’s investment portfolio during the year.